Viral Vectors and Plasmid DNA Manufacturing Market Size Will Attain USD 4.2 Bn By 2030

The global viral vectors and plasmid DNA manufacturing market size accounted for 1.2 billion in 2022 and would grow to USD 4.2 billion by 2030 with a remarkable CAGR of 16.8% between 2022 and 2030.

Viral vectors can be used to introduce genetic material into cells. The transport systems used by viruses to transfer their DNA inside the cells they infect have evolved. Furthermore, retroviruses, adenoviruses, lentiviruses, herpes simplex viruses, and others are examples of viral vectors that can be utilized to insert genetic material into the genetic makeup of cells. By correcting, silencing, or replacing disease-causing faulty genes, gene therapy tries to restore normal function. This therapy is a promising alternative for treating hereditary illnesses like muscular dystrophy and cystic fibrosis as well as cancer, viral infections, and some inherited diseases.

Download a Free Sample Copy of this Report@ https://www.precedenceresearch.com/sample/1012

Market Growth Factors

Due to the increasing prevalence of target afflictions and diseases as well as the efficiency of viral vectors in delivering gene therapy, the market for viral vectors and plasmid DNA synthesis is growing. Continued investigation into gene and cell therapies based on viral vectors and funding for the development of gene therapy both contribute to this development. Viral vectors have a substantially higher level of complications than traditional biologics. The COVID-19 pandemic created a significant opportunity for the creation of viral vectors and plasmid DNA. For market players, creating viral vectors for the SARS-CoV-2 vaccine is also taking on greater importance. In the discovery and development of SARS-CoV-2 vaccines, viral vectors are commonly used as the main delivery method.

Viral Vectors and Plasmid DNA Manufacturing Market Report Scope

Report Highlights

• Vector Type Insights- AAV topped the market in 2019 with a revenue share of over 22.83% of the overall market. Due to their use in the majority of cell-based gene treatments, the production of adeno-associated viral vectors is anticipated to see the highest CAGR growth over the course of the projected period. Due to the significant success of the lentiviral-based gene therapy product in 2017, lentiviral vectors are expected to create considerable income in the years to come. During the forecast period, lentivirus is expected to grow at the highest CAGR of 23.27%, and it is anticipated to reach a market share of 17.41% in 2027.
• Workflow Insights- Due to its highly complicated operations carried out for the purification and polishing of clinical-grade final goods, downstream processing emerged as the dominant workflow segmentation. With a market share of over 61.21% in terms of sales in 2019, downstream processing dominated the market. The sector with the highest predicted CAGR throughout the forecast period is downstream processing, which is expected to reach a market share of 62.81% in 2027.
• Application Insights- Gene therapies, antisense, and RNAi emerged as the dominant vectors in this viral vectors & plasmid DNA market in terms of overall revenue share. With a 37.23% revenue share of the overall market in 2019, gene therapy dominated the market. Gene therapy was valued at USD 158.8 million in the global market in 2019 and is anticipated to reach USD 819.6 million by 2027.
• End-use Insights- The global market for the production of viral vectors and plasmid DNA is segmented into biopharmaceutical, pharmaceutical, and research institution end-users. Pharmaceutical and biopharmaceutical firms are anticipated to control a significant portion of the global vector market by 2020. This expansion is fueled by the ongoing introduction of novel medicines and the ensuing increase in the number of gene therapy-based discovery initiatives by businesses. It is anticipated that more biotech companies will use vectors to produce treatments in the near future.

Regional Analysis

The market for creating viral vectors and plasmid DNA in the US was estimated to be worth USD 211.4 million in 2019 and is anticipated to grow to USD 1,060.2 million by 2027. A total of USD 45.6 million was spent on the manufacturing of viral vectors and plasmid DNA in Canada in 2019. It is anticipated to reach USD 196.3 million by 2027. The financing provided by federal agencies to the region’s cell therapy research foundation is expected to support market expansion in North America.

A growing patient population, more R&D in this area, and other variables are thought to be the reasons why the Asia Pacific region is expected to grow at the quickest rate. Additionally, due to the region’s laxer legal system, patients from western nations are accepted more regularly.

Ask Here for Customization@ https://www.precedenceresearch.com/customization/1012

Market Dynamics

Drivers

Increasing prevalence of target ailment and gene therapy

• Viral vectors & plasmid DNA manufacturing market expansion is being driven by an increase in the prevalence of target ailments & diseases as well as viral vectors’ effectiveness in delivering gene therapy. This development is further aided by ongoing research into viral vector-based gene and cell therapies as well as funding opportunities for gene therapy advancement.

Restraints

Insertional mutagenesis and the high cost of gene therapies

• Market expansion is hampered by the danger of insertional mutagenesis and the high cost of gene therapies. Additionally, technological advancements that solve the limitations of conventional vector production procedures present an alluring possibility for industry producers. Noise during process development is one of the problems preventing this market from expanding. The evaluation of process changes may be hampered by the noise in cell-based tests. Trending is used to establish confidence that an improvement has been made in order to get around this issue.

Opportunities

Rising Demand for Plasmid DNA

• The global industry is being driven by an increase in the number of patients choosing gene therapy. The demand for plasmid DNA is soaring as gene therapy research and development picks up steam. Thus, pDNA (Plasmid DNA) production is necessary for Adeno-associated virus (AAV), lentivirus, and other viral vector systems. Additionally, a number of hereditary disorders and infectious diseases are spreading across the globe. For instance, according to UNAIDS figures, 1.7 million persons acquired HIV in 2019 and 38.0 million people worldwide were living with the disease.

Recent Developments

• A multi-phase expansion of its plasmid DNA services as well as a continuation of its gene therapy services growth effort for viral vectors and plasmid DNA was announced by Cognate BioServices’ gene therapy business, Cobra biologics, on January 19, 2021. For the clinical manufacture of immuno-oncology drugs like AAV, lentiviral vector, and CRISPR products, the HQ plasmid manufacturing service offers a six-week turnaround time.
• Thermo Fisher Scientific Inc., a leader in the field of scientific services, and Groupe Novasep SAS (Novasep), a significant supplier of services and products to the life sciences sector, jointly announced on January 15, 2021 that Thermo Fisher had purchased Henogen S.A., Novasep’s viral vector production company in Belgium, for about 725 million euros in cash.

Some of the key players in the viral vectors and plasmid DNA manufacturing market include:

• Novasep
• Aldevron
• MerckWaismanBiomanufacturing
• Creative Biogene
• The Cell and Gene Therapy Catapult
• Cobra Biologics
• uniQure N.V.
• Addgene
• FUJIFILM Holdings Corporation
• Oxford Biomedicaplc
• Takara Bio Inc.

Market Segmentation

By Vector Type

• Adenovirus
• Plasmid DNA
• Lentivirus
• Retrovirus
• AAV
• Others

By Application

• Gene Therapy
• Antisense &RNAi
• Cell Therapy
• Vaccinology

By Workflow

• Upstream Processing
  • Vector Recovery/Harvesting
  • Vector Amplification & Expansion
• Downstream Processing
  • Fill-finish
  • Purification

By End-User

• Biopharmaceutical and Pharmaceutical Companies
• Research Institutes

By Disease

• Genetic Disorders
• Cancer
• Infectious Diseases
• Others

Regional Segmentation

• North America (U.S., Canada, Mexico)
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
• Latin America (Brazil and Rest of Latin America)
• Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Click Here to View Full Report Table of Contents

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/1012

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333